Cyclophosphamide, vindesine and oral VP-16 in the treatment of non-small cell lung cancer (NSCLC): an outpatient regimen.
Twenty-five evaluable patients with non-small cell carcinoma of the lung were treated with cyclophosphamide, vindesine and oral VP-16 in the outpatient setting. The overall response rate was 44% and the median survival was 4.9 months (7.25 months in responders).
Weitberg
A B
AB
Division of Hematology/Oncology, Roger Williams General Hospital Cancer Center, Providence, R.I.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D014751:Vindesine / Q000008:administration & dosage
D005047:Etoposide; D003520:Cyclophosphamide; D014751:Vindesine